Treatment of extensive small cell lung cancer

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Despite initial chemosensitivity, increasing long-term survival in SCLC remains an elusive goal. In a patient population in which our goals are to palliate, maintaining quality of life and minimizing toxicity are equally important objectives. This latter point appears particularly pertinent to the quest for increased dose intensity in extensive-stage SCLC. SCLC patients tend to be older and commonly manifest comorbidities such as cardiovascular and obstructive lung disease that make them poor candidates for dose-intense therapy. The most promising therapeutic results of the last 20 yearsthe data from the Japanese Clinical Oncology Group with irinotecan and Pare based not on the concepts of dose intensity but rather on the concepts of drug diversity. It is hoped that these data will be confirmed by ongoing trials. Lastly, it is anticipated that selective antineoplastic therapies that target the underlying molecular abnormalities that characterize SCLC will offer promise for the future.

Original languageEnglish (US)
Pages (from-to)373-385
Number of pages13
JournalHematology/Oncology Clinics of North America
Volume18
Issue number2
DOIs
StatePublished - Apr 2004

Fingerprint

Small Cell Lung Carcinoma
irinotecan
Obstructive Lung Diseases
Medical Oncology
Antineoplastic Agents
Comorbidity
Therapeutics
Quality of Life
Survival
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Treatment of extensive small cell lung cancer. / Davies, Angela M.; Lara, Primo N; Lau, Derick H; Gandara, David R.

In: Hematology/Oncology Clinics of North America, Vol. 18, No. 2, 04.2004, p. 373-385.

Research output: Contribution to journalArticle

@article{b35efc3c7bcd46389db49ba7a7f6728e,
title = "Treatment of extensive small cell lung cancer",
abstract = "Despite initial chemosensitivity, increasing long-term survival in SCLC remains an elusive goal. In a patient population in which our goals are to palliate, maintaining quality of life and minimizing toxicity are equally important objectives. This latter point appears particularly pertinent to the quest for increased dose intensity in extensive-stage SCLC. SCLC patients tend to be older and commonly manifest comorbidities such as cardiovascular and obstructive lung disease that make them poor candidates for dose-intense therapy. The most promising therapeutic results of the last 20 yearsthe data from the Japanese Clinical Oncology Group with irinotecan and Pare based not on the concepts of dose intensity but rather on the concepts of drug diversity. It is hoped that these data will be confirmed by ongoing trials. Lastly, it is anticipated that selective antineoplastic therapies that target the underlying molecular abnormalities that characterize SCLC will offer promise for the future.",
author = "Davies, {Angela M.} and Lara, {Primo N} and Lau, {Derick H} and Gandara, {David R}",
year = "2004",
month = "4",
doi = "10.1016/j.hoc.2003.12.012",
language = "English (US)",
volume = "18",
pages = "373--385",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of extensive small cell lung cancer

AU - Davies, Angela M.

AU - Lara, Primo N

AU - Lau, Derick H

AU - Gandara, David R

PY - 2004/4

Y1 - 2004/4

N2 - Despite initial chemosensitivity, increasing long-term survival in SCLC remains an elusive goal. In a patient population in which our goals are to palliate, maintaining quality of life and minimizing toxicity are equally important objectives. This latter point appears particularly pertinent to the quest for increased dose intensity in extensive-stage SCLC. SCLC patients tend to be older and commonly manifest comorbidities such as cardiovascular and obstructive lung disease that make them poor candidates for dose-intense therapy. The most promising therapeutic results of the last 20 yearsthe data from the Japanese Clinical Oncology Group with irinotecan and Pare based not on the concepts of dose intensity but rather on the concepts of drug diversity. It is hoped that these data will be confirmed by ongoing trials. Lastly, it is anticipated that selective antineoplastic therapies that target the underlying molecular abnormalities that characterize SCLC will offer promise for the future.

AB - Despite initial chemosensitivity, increasing long-term survival in SCLC remains an elusive goal. In a patient population in which our goals are to palliate, maintaining quality of life and minimizing toxicity are equally important objectives. This latter point appears particularly pertinent to the quest for increased dose intensity in extensive-stage SCLC. SCLC patients tend to be older and commonly manifest comorbidities such as cardiovascular and obstructive lung disease that make them poor candidates for dose-intense therapy. The most promising therapeutic results of the last 20 yearsthe data from the Japanese Clinical Oncology Group with irinotecan and Pare based not on the concepts of dose intensity but rather on the concepts of drug diversity. It is hoped that these data will be confirmed by ongoing trials. Lastly, it is anticipated that selective antineoplastic therapies that target the underlying molecular abnormalities that characterize SCLC will offer promise for the future.

UR - http://www.scopus.com/inward/record.url?scp=1942503924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942503924&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2003.12.012

DO - 10.1016/j.hoc.2003.12.012

M3 - Article

C2 - 15094177

AN - SCOPUS:1942503924

VL - 18

SP - 373

EP - 385

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -